Dompé Farmaceutici S.p.a
Clinical trials sponsored by Dompé Farmaceutici S.p.a, explained in plain language.
-
New drug fails to show benefit in severe COVID-19 pneumonia trial
Disease control TerminatedThis study tested whether adding reparixin to standard care could prevent death or the need for a breathing machine in hospitalized adults with COVID-19 or other pneumonia. About 414 participants were planned, but the trial was stopped early. The goal was to see if reparixin redu…
Phase: PHASE3 • Sponsor: Dompé Farmaceutici S.p.A • Aim: Disease control
Last updated May 17, 2026 10:26 UTC
-
Can a pill save Insulin-Making cells in new type 1 diabetes?
Disease control TerminatedThis study tested an oral drug called ladarixin in people aged 14-45 recently diagnosed with type 1 diabetes. The goal was to see if it could protect the pancreas cells that make insulin, slowing the disease. The trial was stopped early, and results are being analyzed.
Phase: PHASE2 • Sponsor: Dompé Farmaceutici S.p.A • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Sjögren's dry eye: are nerves in the cornea damaged?
Knowledge-focused TerminatedThis study looked at how often people with Sjögren's dry eye have reduced feeling in their cornea (the clear front part of the eye). Researchers measured corneal sensitivity, tear production, and pain in 103 adults with confirmed Sjögren's syndrome and dry eye. No treatments were…
Sponsor: Dompé Farmaceutici S.p.A • Aim: Knowledge-focused
Last updated May 06, 2026 16:01 UTC